Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

Since dacarbazine was approved for treating metastatic melanoma in the 1970s, numerous
studies have evaluated whether different schedules and dacarbazine-based combinations …

We undertook a systematic review of 41 randomised studies in disseminated melanoma,
identified by a comprehensive search. We aimed to investigate rates of response to various …

BACKGROUND: The alpha v beta 3 (αvβ3) integrin is involved in intracellular signaling
regulating cell proliferation, migration, and differentiation and is important for tumor‐induced …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Melanoma is a neoplasm with a rising incidence. Early‐stage melanoma is curable, but
advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced …

Metastatic melanoma remains a lethal disease with a long-term remission rate of less than
10%. Despite many years of research, there has not been a new drug approved in this …

Self‐renewing cancer stem cells (CSC) capable of spawning more differentiated tumor cell
progeny are required for tumorigenesis and neoplastic progression of leukemias and …

Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing
incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and …

A variety of immunotherapeutic approaches have shown activity in patients with metastatic
melanoma with the best results being observed with interleukin 2 (IL-2). Follow-up data …